50 Studies Every Endocrinologist Should Know
-10%
portes grátis
50 Studies Every Endocrinologist Should Know
Classic Endocrinology
Interlandi, John
Oxford University Press Inc
01/2026
448
Mole
Inglês
9780197684702
15 a 20 dias
Descrição não disponível.
SECTION 1: Conditions caused by Thyroid Damage
Chapter 1: Screening for Thyroid Disease in Early Pregnancy and in Pre-Pregnancy
Chapter 2: Subclinical Hypothyroidism
Chapter 3: Management of Thyroxine in Non-Ablated Patients with Hypothyroidism
Chapter 4: Optimal Thyroid Replacement for the Athyreotic Patient
SECTION 2: Conditions Causing Thyroid Overactivity
Chapter 5: Antithyroid Drugs vs. Ablation in Community Treatment for Graves>' Disease
Chapter 6: Optimum Use of Antithyroid Drugs in Hyperthyroidism
Chapter 7: Risks of I-131 Treatment of Hyperthyroidism
Chapter 8: Hyperthyroidism caused by Amiodarone (AIT)
SECTION 3: Focal and Structural Thyroid Disease
Chapter 9: Selection of Thyroid Nodules to be Biopsied
Chapter 10: Selection of Patients over 45 for Thyroid Biopsy
Chapter 11: Molecular Genomic Testing (MGT) for Indeterminate Thyroid Nodules
Chapter 12: Complication Rate(s) from Thyroidectomy
Chapter 13: Ablation Techniques for Benign or Hot Nodules
Chapter 14: Microscopic Papillary Thyroid Carcinoma (mPTC) and Active Surveillance (AS)
Chapter 15: Optimal Work-up and Surgery for a small, non-metastatic DTCA
Chapter 16: I-131 Treatment for DTCA
SECTION 4: Parathyroid Diseases
Chapter 17: Active Surveillance and/or Medical Therapy for Hyperparathyroidism in Older Patients
Chapter 18: Preoperative Localization of Sporadic Primary Hyperparathyroidism
Chapter 19: Quality of Life after Surgery for Mild/Moderate Sporadic Primary Hyperparathyroidism
Chapter 20: Secondary Hyperparathyroidism, Idiopathic Hypercalciuria, and Bone Density
Chapter 21: Recurrent and/or Persistent Primary Hyperparathyroidism
SECTION 5: Metabolic Bone Disease
Chapter 22: Calcium and Vitamin D Effects on Bone Mass
Chapter 23: Fracture Prevention in Patients with Low Bone Mass
Chapter 24: Pretreatment Evaluation for Osteoporosis
Chapter 25: Evaluation of Fracture Risk in Osteoporosis
Chapter 26: Osteoporosis and Hip Fracture Prevention
Chapter 27: Alendronate and Fracture Risk Reduction
Chapter 28: Hip Fracture in the Elderly with Very Low Bone Density
Chapter 29: Anabolic Agent(s) for Osteoporosis
Chapter 30: Glucocorticoid Osteoporosis
Chapter 31: Osteoporosis in Men
SECTION 6: Adrenal Conditions
Chapter 32: The Importance of Recognizing Hyperaldosteronism
Chapter 33: Effectiveness of Treatment of Hyperaldosteronism
Chapter 34: Screening for Adrenal Insufficiency
Chapter 35: Adrenal Incidentalomas
Chapter 36: Opioid-Induced Endocrine Deficiencies
Chapter 37: Adrenal Insufficiency from Corticosteroid Treatment
Chapter 38: Optimal Testing for ACTH-Dependent Hypercortisolism
SECTION 7: Pituitary Tumors / Hypercortisolism
Chapter 39: Duration of Medical Treatment of Intrasellar Prolactinomas
Chapter 40: Acromegaly Treatment-Surgery, Medication, or What?
Chapter 41: Primary Treatment of Pituitary Hypercortisolism
Chapter 42: Treatment of Recurrent or Persistent Hypercortisolism
SECTION 8: Conditions Caused by Testosterone Deficiency
Chapter 43: Risks of Testosterone Treatment in Older Men
Chapter 44: Male Obesity Secondary Hypogonadism (MOSH)
SECTION 9: Conditions Related to Estrogen Deficiency
Chapter 45: Estrogen Treatment and Cardiovascular Health
Chapter 46: Estrogen Treatment and Skeletal Health
Chapter 47: Estrogen + Progestin vs. Estrogen Alone, and Neoplasia
SECTION 10: Polycystic Ovary Syndrome
Chapter 48: Optimal Differential Diagnosis of PCOS
Chapter 49: Optimal Treatment of Hirsutism in PCOS
Chapter 50: Treatment of Subfertility in PCOS
Chapter 1: Screening for Thyroid Disease in Early Pregnancy and in Pre-Pregnancy
Chapter 2: Subclinical Hypothyroidism
Chapter 3: Management of Thyroxine in Non-Ablated Patients with Hypothyroidism
Chapter 4: Optimal Thyroid Replacement for the Athyreotic Patient
SECTION 2: Conditions Causing Thyroid Overactivity
Chapter 5: Antithyroid Drugs vs. Ablation in Community Treatment for Graves>' Disease
Chapter 6: Optimum Use of Antithyroid Drugs in Hyperthyroidism
Chapter 7: Risks of I-131 Treatment of Hyperthyroidism
Chapter 8: Hyperthyroidism caused by Amiodarone (AIT)
SECTION 3: Focal and Structural Thyroid Disease
Chapter 9: Selection of Thyroid Nodules to be Biopsied
Chapter 10: Selection of Patients over 45 for Thyroid Biopsy
Chapter 11: Molecular Genomic Testing (MGT) for Indeterminate Thyroid Nodules
Chapter 12: Complication Rate(s) from Thyroidectomy
Chapter 13: Ablation Techniques for Benign or Hot Nodules
Chapter 14: Microscopic Papillary Thyroid Carcinoma (mPTC) and Active Surveillance (AS)
Chapter 15: Optimal Work-up and Surgery for a small, non-metastatic DTCA
Chapter 16: I-131 Treatment for DTCA
SECTION 4: Parathyroid Diseases
Chapter 17: Active Surveillance and/or Medical Therapy for Hyperparathyroidism in Older Patients
Chapter 18: Preoperative Localization of Sporadic Primary Hyperparathyroidism
Chapter 19: Quality of Life after Surgery for Mild/Moderate Sporadic Primary Hyperparathyroidism
Chapter 20: Secondary Hyperparathyroidism, Idiopathic Hypercalciuria, and Bone Density
Chapter 21: Recurrent and/or Persistent Primary Hyperparathyroidism
SECTION 5: Metabolic Bone Disease
Chapter 22: Calcium and Vitamin D Effects on Bone Mass
Chapter 23: Fracture Prevention in Patients with Low Bone Mass
Chapter 24: Pretreatment Evaluation for Osteoporosis
Chapter 25: Evaluation of Fracture Risk in Osteoporosis
Chapter 26: Osteoporosis and Hip Fracture Prevention
Chapter 27: Alendronate and Fracture Risk Reduction
Chapter 28: Hip Fracture in the Elderly with Very Low Bone Density
Chapter 29: Anabolic Agent(s) for Osteoporosis
Chapter 30: Glucocorticoid Osteoporosis
Chapter 31: Osteoporosis in Men
SECTION 6: Adrenal Conditions
Chapter 32: The Importance of Recognizing Hyperaldosteronism
Chapter 33: Effectiveness of Treatment of Hyperaldosteronism
Chapter 34: Screening for Adrenal Insufficiency
Chapter 35: Adrenal Incidentalomas
Chapter 36: Opioid-Induced Endocrine Deficiencies
Chapter 37: Adrenal Insufficiency from Corticosteroid Treatment
Chapter 38: Optimal Testing for ACTH-Dependent Hypercortisolism
SECTION 7: Pituitary Tumors / Hypercortisolism
Chapter 39: Duration of Medical Treatment of Intrasellar Prolactinomas
Chapter 40: Acromegaly Treatment-Surgery, Medication, or What?
Chapter 41: Primary Treatment of Pituitary Hypercortisolism
Chapter 42: Treatment of Recurrent or Persistent Hypercortisolism
SECTION 8: Conditions Caused by Testosterone Deficiency
Chapter 43: Risks of Testosterone Treatment in Older Men
Chapter 44: Male Obesity Secondary Hypogonadism (MOSH)
SECTION 9: Conditions Related to Estrogen Deficiency
Chapter 45: Estrogen Treatment and Cardiovascular Health
Chapter 46: Estrogen Treatment and Skeletal Health
Chapter 47: Estrogen + Progestin vs. Estrogen Alone, and Neoplasia
SECTION 10: Polycystic Ovary Syndrome
Chapter 48: Optimal Differential Diagnosis of PCOS
Chapter 49: Optimal Treatment of Hirsutism in PCOS
Chapter 50: Treatment of Subfertility in PCOS
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
SECTION 1: Conditions caused by Thyroid Damage
Chapter 1: Screening for Thyroid Disease in Early Pregnancy and in Pre-Pregnancy
Chapter 2: Subclinical Hypothyroidism
Chapter 3: Management of Thyroxine in Non-Ablated Patients with Hypothyroidism
Chapter 4: Optimal Thyroid Replacement for the Athyreotic Patient
SECTION 2: Conditions Causing Thyroid Overactivity
Chapter 5: Antithyroid Drugs vs. Ablation in Community Treatment for Graves>' Disease
Chapter 6: Optimum Use of Antithyroid Drugs in Hyperthyroidism
Chapter 7: Risks of I-131 Treatment of Hyperthyroidism
Chapter 8: Hyperthyroidism caused by Amiodarone (AIT)
SECTION 3: Focal and Structural Thyroid Disease
Chapter 9: Selection of Thyroid Nodules to be Biopsied
Chapter 10: Selection of Patients over 45 for Thyroid Biopsy
Chapter 11: Molecular Genomic Testing (MGT) for Indeterminate Thyroid Nodules
Chapter 12: Complication Rate(s) from Thyroidectomy
Chapter 13: Ablation Techniques for Benign or Hot Nodules
Chapter 14: Microscopic Papillary Thyroid Carcinoma (mPTC) and Active Surveillance (AS)
Chapter 15: Optimal Work-up and Surgery for a small, non-metastatic DTCA
Chapter 16: I-131 Treatment for DTCA
SECTION 4: Parathyroid Diseases
Chapter 17: Active Surveillance and/or Medical Therapy for Hyperparathyroidism in Older Patients
Chapter 18: Preoperative Localization of Sporadic Primary Hyperparathyroidism
Chapter 19: Quality of Life after Surgery for Mild/Moderate Sporadic Primary Hyperparathyroidism
Chapter 20: Secondary Hyperparathyroidism, Idiopathic Hypercalciuria, and Bone Density
Chapter 21: Recurrent and/or Persistent Primary Hyperparathyroidism
SECTION 5: Metabolic Bone Disease
Chapter 22: Calcium and Vitamin D Effects on Bone Mass
Chapter 23: Fracture Prevention in Patients with Low Bone Mass
Chapter 24: Pretreatment Evaluation for Osteoporosis
Chapter 25: Evaluation of Fracture Risk in Osteoporosis
Chapter 26: Osteoporosis and Hip Fracture Prevention
Chapter 27: Alendronate and Fracture Risk Reduction
Chapter 28: Hip Fracture in the Elderly with Very Low Bone Density
Chapter 29: Anabolic Agent(s) for Osteoporosis
Chapter 30: Glucocorticoid Osteoporosis
Chapter 31: Osteoporosis in Men
SECTION 6: Adrenal Conditions
Chapter 32: The Importance of Recognizing Hyperaldosteronism
Chapter 33: Effectiveness of Treatment of Hyperaldosteronism
Chapter 34: Screening for Adrenal Insufficiency
Chapter 35: Adrenal Incidentalomas
Chapter 36: Opioid-Induced Endocrine Deficiencies
Chapter 37: Adrenal Insufficiency from Corticosteroid Treatment
Chapter 38: Optimal Testing for ACTH-Dependent Hypercortisolism
SECTION 7: Pituitary Tumors / Hypercortisolism
Chapter 39: Duration of Medical Treatment of Intrasellar Prolactinomas
Chapter 40: Acromegaly Treatment-Surgery, Medication, or What?
Chapter 41: Primary Treatment of Pituitary Hypercortisolism
Chapter 42: Treatment of Recurrent or Persistent Hypercortisolism
SECTION 8: Conditions Caused by Testosterone Deficiency
Chapter 43: Risks of Testosterone Treatment in Older Men
Chapter 44: Male Obesity Secondary Hypogonadism (MOSH)
SECTION 9: Conditions Related to Estrogen Deficiency
Chapter 45: Estrogen Treatment and Cardiovascular Health
Chapter 46: Estrogen Treatment and Skeletal Health
Chapter 47: Estrogen + Progestin vs. Estrogen Alone, and Neoplasia
SECTION 10: Polycystic Ovary Syndrome
Chapter 48: Optimal Differential Diagnosis of PCOS
Chapter 49: Optimal Treatment of Hirsutism in PCOS
Chapter 50: Treatment of Subfertility in PCOS
Chapter 1: Screening for Thyroid Disease in Early Pregnancy and in Pre-Pregnancy
Chapter 2: Subclinical Hypothyroidism
Chapter 3: Management of Thyroxine in Non-Ablated Patients with Hypothyroidism
Chapter 4: Optimal Thyroid Replacement for the Athyreotic Patient
SECTION 2: Conditions Causing Thyroid Overactivity
Chapter 5: Antithyroid Drugs vs. Ablation in Community Treatment for Graves>' Disease
Chapter 6: Optimum Use of Antithyroid Drugs in Hyperthyroidism
Chapter 7: Risks of I-131 Treatment of Hyperthyroidism
Chapter 8: Hyperthyroidism caused by Amiodarone (AIT)
SECTION 3: Focal and Structural Thyroid Disease
Chapter 9: Selection of Thyroid Nodules to be Biopsied
Chapter 10: Selection of Patients over 45 for Thyroid Biopsy
Chapter 11: Molecular Genomic Testing (MGT) for Indeterminate Thyroid Nodules
Chapter 12: Complication Rate(s) from Thyroidectomy
Chapter 13: Ablation Techniques for Benign or Hot Nodules
Chapter 14: Microscopic Papillary Thyroid Carcinoma (mPTC) and Active Surveillance (AS)
Chapter 15: Optimal Work-up and Surgery for a small, non-metastatic DTCA
Chapter 16: I-131 Treatment for DTCA
SECTION 4: Parathyroid Diseases
Chapter 17: Active Surveillance and/or Medical Therapy for Hyperparathyroidism in Older Patients
Chapter 18: Preoperative Localization of Sporadic Primary Hyperparathyroidism
Chapter 19: Quality of Life after Surgery for Mild/Moderate Sporadic Primary Hyperparathyroidism
Chapter 20: Secondary Hyperparathyroidism, Idiopathic Hypercalciuria, and Bone Density
Chapter 21: Recurrent and/or Persistent Primary Hyperparathyroidism
SECTION 5: Metabolic Bone Disease
Chapter 22: Calcium and Vitamin D Effects on Bone Mass
Chapter 23: Fracture Prevention in Patients with Low Bone Mass
Chapter 24: Pretreatment Evaluation for Osteoporosis
Chapter 25: Evaluation of Fracture Risk in Osteoporosis
Chapter 26: Osteoporosis and Hip Fracture Prevention
Chapter 27: Alendronate and Fracture Risk Reduction
Chapter 28: Hip Fracture in the Elderly with Very Low Bone Density
Chapter 29: Anabolic Agent(s) for Osteoporosis
Chapter 30: Glucocorticoid Osteoporosis
Chapter 31: Osteoporosis in Men
SECTION 6: Adrenal Conditions
Chapter 32: The Importance of Recognizing Hyperaldosteronism
Chapter 33: Effectiveness of Treatment of Hyperaldosteronism
Chapter 34: Screening for Adrenal Insufficiency
Chapter 35: Adrenal Incidentalomas
Chapter 36: Opioid-Induced Endocrine Deficiencies
Chapter 37: Adrenal Insufficiency from Corticosteroid Treatment
Chapter 38: Optimal Testing for ACTH-Dependent Hypercortisolism
SECTION 7: Pituitary Tumors / Hypercortisolism
Chapter 39: Duration of Medical Treatment of Intrasellar Prolactinomas
Chapter 40: Acromegaly Treatment-Surgery, Medication, or What?
Chapter 41: Primary Treatment of Pituitary Hypercortisolism
Chapter 42: Treatment of Recurrent or Persistent Hypercortisolism
SECTION 8: Conditions Caused by Testosterone Deficiency
Chapter 43: Risks of Testosterone Treatment in Older Men
Chapter 44: Male Obesity Secondary Hypogonadism (MOSH)
SECTION 9: Conditions Related to Estrogen Deficiency
Chapter 45: Estrogen Treatment and Cardiovascular Health
Chapter 46: Estrogen Treatment and Skeletal Health
Chapter 47: Estrogen + Progestin vs. Estrogen Alone, and Neoplasia
SECTION 10: Polycystic Ovary Syndrome
Chapter 48: Optimal Differential Diagnosis of PCOS
Chapter 49: Optimal Treatment of Hirsutism in PCOS
Chapter 50: Treatment of Subfertility in PCOS
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
